Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 17, 2026

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

LGL leukemia and HTLV.

Anish Thomas1, Raisa Perzova, Lynn Abbott

  • 1Department of Medicine, State University of New York, Upstate Medical University, Syracuse, 13202, USA.

AIDS Research and Human Retroviruses
|January 6, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Oncology Research Information Exchange Network (ORIEN) - Building a Real-World Collaborative, Patient-driven Infrastructure for Discovery Research and Precision Oncology.

Research square·2026
Same author

Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies.

Frontiers in oncology·2026
Same author

Treatment and Outcomes for Acute Ischemic Stroke in Cardiomyopathy Patients With Heart Failure: A Retrospective Cross-Sectional Study.

Cardiology in review·2026
Same author

Bidirectional coupling among EMT, AXL-RB1 signaling and lineage switch drives resistance to osimertinib and worse clinical outcomes in NSCLC.

bioRxiv : the preprint server for biology·2026
Same author

HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-driven small cell lung cancer.

Molecular cancer therapeutics·2026
Same author

BLOCKADE OF TUMOR-INTRINSIC TGF-Β SIGNALING DRIVES HYPERPROGRESSION IN SMALL CELL LUNG CANCER.

Cancer discovery·2026

Large granular lymphocytic leukemia (LGLL) patients show higher rates of Human T-lymphotropic virus (HTLV) antibodies. A small subset of LGLL patients were infected with HTLV-2, suggesting a potential role in disease etiology.

Area of Science:

  • Immunology
  • Virology
  • Oncology

Background:

  • Large granular lymphocytic leukemia (LGLL) is a rare hematologic disorder.
  • Human T-lymphotropic virus (HTLV) infection is associated with various lymphoproliferative diseases.

Purpose of the Study:

  • To investigate the prevalence of HTLV infection and antibodies in LGLL patients.
  • To explore potential cross-reactivity with human endogenous retroviral elements.

Main Methods:

  • Sera and DNA samples from 53 LGLL patients and 10,000 volunteer blood donors (VBD) were analyzed.
  • Enzyme immunoassay (EIA), peptide-specific Western blots (WB), and PCR were used for HTLV screening and typing.
  • Antibodies to Human Endogenous Retroviral Element K10 (HERV K10) were also assessed.

Related Experiment Videos

Last Updated: Jun 17, 2026

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

Main Results:

  • Forty-four percent of LGLL patients had anti-HTLV antibodies compared to 0.12% of VBD (p < 0.001).
  • HTLV-2 infection was confirmed in 7.5% of LGLL patients versus 0.01% of VBD (p < 0.001).
  • LGLL patients showed higher reactivity to HERV K10 peptides, suggesting possible cross-reactivity.

Conclusions:

  • HTLV-2 infection may contribute to a minority of LGLL cases.
  • The observed anti-HTLV seroreactivity in LGLL warrants further investigation into its clinical significance.
  • Cross-reactivity with HERV K10 is a potential factor influencing serological findings.